XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Total revenues $ 3,191 $ 1,517 $ 5,845 $ 2,752
Operating expenses:        
Research and development 45,263 34,535 116,611 87,585
General and administrative 10,054 8,221 28,285 22,082
Total operating expenses 55,317 42,756 144,896 109,667
Operating loss (52,126) (41,239) (139,051) (106,915)
Investment and other income, net 10,005 2,979 28,280 8,792
Net loss $ (42,121) $ (38,260) $ (110,771) $ (98,123)
Basic net loss per common share (in dollars per share) $ (0.64) $ (0.81) $ (1.74) $ (2.08)
Diluted net loss per common share (in dollars per share) $ (0.64) $ (0.81) $ (1.74) $ (2.08)
Shares used in calculating basic net loss per share (in shares) 66,294 47,261 63,737 47,243
Shares used in calculating diluted net loss per share (in shares) 66,294 47,261 63,737 47,243
Comprehensive loss:        
Net loss $ (42,121) $ (38,260) $ (110,771) $ (98,123)
Other comprehensive income (loss):        
Unrealized gain on marketable securities 3,508 63 1,980 875
Comprehensive loss (38,613) (38,197) (108,791) (97,248)
Product development and licensing agreements        
Revenues:        
Total revenues 3 2 5 19
Contracts and grants        
Revenues:        
Total revenues $ 3,188 $ 1,515 $ 5,840 $ 2,733